Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP3A41B and CYP3A53 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.

Annals of transplantation - 1 Jan 2000

Żochowska Dorota, Wyzgał Janusz, Pączek Leszek

Abstract excerpt

BACKGROUND: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors (sirolimus, SRL) - immunosuppressants used to prevent allograft rejection after renal transplantation - have a narrow therapeutic index and show considerable inter-individual pharmacokinetic differences. Differences in expression and activity of cytochrome P450 (CYP) 3A4 and 3A5 affect these pharmacokinetics; cytochrome activity differences...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclosporine
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Individuality

Share to Kidney Transplantation

Share to Sirolimus

Source

Identifiers

PMID: 23018254
DOI: 10.12659/aot.883456

Genes

SRL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.PMID 23018254Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.Semantic proximity Read ↗

The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.Semantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.Semantic proximity Read ↗

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.Semantic proximity Read ↗

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted PatientsSemantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.Semantic proximity Read ↗

Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.Semantic proximity Read ↗

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.Semantic proximity Read ↗

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.